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22 ABSTRACT
23 The development of new agents to target HBV cccDNA is urgently needed 
24 because of the limitations of current available drugs for treatment of hepatitis B. By 
25 using a cell-based assay in which the production of HBeAg is in a cccDNA-
26 dependent manner，we screened a compound library derived from Chinese herbal 
27 remedies for inhibitors against HBV cccDNA. Three hydrolyzable tannins, 
28 specifically punicalagin, punicalin and geraniin, emerged as novel anti-HBV agents. 
29 These compounds significantly reduced the production of secreted HBeAg and 
30 cccDNA in a dose-dependent manner in our assay, without dramatic alteration of 
31 viral DNA replication. Furthermore, punicalagin did not affect precore/core 
32 promoter activity, pgRNA transcription, core protein expression, or HBsAg secretion. 
33 By employing the cell-based cccDNA accumulation and stability assay, we found 
34 that these tannins significantly inhibited the establishment of cccDNA and modestly 
35 facilitated the degradation of preexisting cccDNA. Collectively, our results suggest 
36 that hydrolyzable tannins inhibit HBV cccDNA production via a dual mechanism 
37 through preventing the formation of cccDNA and promoting cccDNA decay, 
38 although the latter effect is rather minor. These hydrolyzable tannins may serve as 
39 lead compounds for the development of new agents to cure HBV infection.
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344 1. INTRODUCTION
45 Hepatitis B virus (HBV) infection remains a major global health problem with 
46 an estimated 240 million chronically infected people worldwide (Grimm et al., 2011; 
47 Zeisel et al., 2015). Every year approximately 1 million people die of severe liver 
48 diseases caused by chronic hepatitis B (CHB) infection, such as liver failure, 
49 cirrhosis and hepatocellular carcinoma (HCC) (Ganem and Prince, 2004; Grimm et 
50 al., 2011; Hoofnagle et al., 2007). HBV is a small double-stranded DNA virus 
51 belonging to the family of Hepadnaviridae. After an endocytotic process, the viral 
52 nucleocapsid is released into cytoplasm and the 3.2kb relaxed circular partially 
53 double-stranded DNA (rcDNA) is transferred to nucleus where the rcDNA is 
54 repaired to form covalently closed circular DNA (cccDNA) by host functions (Guo 
55 and Guo, 2015; Summers et al., 1975; Tuttleman et al., 1986). This episomal 
56 cccDNA serves as the transcription template for production of 3.5 kb pregenomic 
57 RNA (pgRNA) and four other viral mRNAs under the control of their own 
58 promoters, specifically 3.5 kb precore mRNA, 2.4 kb and 2.1 kb surface mRNA, and 
59 0.7 kb X mRNA. The 3.5 kb precore mRNA contains all the ORFs of viral proteins 
60 but only translates precore protein, which is further processed and secreted as e 
61 antigen (HBeAg). The pgRNA is a multifunctional transcript which encodes the viral 
62 polymerase and core protein, and it serves as the template of HBV genome DNA 
63 synthesis as well. Following the binding of viral polymerase to pgRNA，the 
64 complex is packaged into nucleocapsid, inside of which the pgRNA is converted to 
65 rcDNA by polymerase. The mature nucleocapsid can either acquire the viral 
66 envelope and secrete as virion or redirect the rcDNA into nucleus to refill the 
67 cccDNA pool (Ganem and Varmus, 1987; Seeger and Mason, 2000; Tuttleman et al., 
68 1986; Wu et al., 1990). Therefore, cccDNA plays a pivotal role in HBV life cycle 
469 and its elimination is critical for a cure of hepatitis B. 
70 Although vaccination programs against HBV infection have shown a high 
71 efficiency in blocking vertical transmission and protect 90% health people from 
72 infection with HBV, an 100% effective antiviral treatment has not been available for 
73 patients with CHB yet (Raney et al., 2003; Shepard et al., 2006; Thermet et al., 
74 2003). There are currently two major classes of drugs approved for the treatment of 
75 CHB in Europe and the US, namely interferons (IFN-α and pegylated IFN-α) and 
76 nucleotide analogues (lamivudine, adefovir, entecavir, telbivudine, and tenofovir) 
77 (Zoulim and Durantel, 2015). Each agent has individual advantages and drawbacks. 
78 Interferon is costly, poorly tolerated, and only responsive in a small fraction of CHB 
79 patients. Nucleotide analogues can effectively inhibit HBV DNA synthesis, but drug 
80 resistance emerges after long-term treatment. More importantly, cccDNA persists 
81 even after years of antiviral therapy and results in rapid reactivation of viral 
82 replication upon withdrawal of treatment (Khanbabaee and van Ree, 2001; Litwin et 
83 al., 2005; Locarnini, 2005; Moraleda et al., 1997; Zoulim, 2005). In recent years, 
84 several non-nucleotide substances with novel antiviral targets have been evaluated in 
85 preclinical studies or clinical trials for their anti-HBV activities. For example, 
86 Petersen et.al showed that the acylated PreS1-derived peptides could prevent HBV 
87 infection of immunodeficient uPA mice repopulated with primary human 
88 hepatocytes (Petersen et al., 2008). AT-61 and AT-130, the phenylpropenamide 
89 derivatives, interfere with the packing of pgRNA into core particles (Delaney et al., 
90 2002; Deres et al., 2003; King et al., 1998). Heteroaryldihydropyrimidines (HAPs) 
91 inhibit HBV capsid formation through altering the kinetics of capsid assembly and/or 
92 promoting the degradation of capsid protein (Deres et al., 2003; Stray et al., 2005). 
93 However, a complete eradication of viral cccDNA from the nuclei of infected 
594 hepatocytes cannot be achieved by any of the aforementioned drugs and compounds. 
95 Thus, the development of new drugs preventing the formation of cccDNA, or ideally, 
96 eliminating established cccDNA, in the infected hepatocytes, is of special clinical 
97 interest (Levrero et al., 2009; Zoulim and Locarnini, 2009). 
98 In a previous attempt to find small molecules that can inhibit HBV cccDNA 
99 accumulation, Cai et al screened a compound library by using HepDE19 cell system 
100 which inducibly expresses cccDNA-dependent HBeAg as a surrogate marker for 
101 cccDNA, and identified two structurally related compounds that act as cccDNA 
102 formation inhibitors through blocking rcDNA deproteinization (removal of the 
103 covalently attached polymerase from rcDNA), a presumably mandatory step in the 
104 conversion of rcDNA to cccDNA (Cai et al., 2012). In this report, we utilized a cell 
105 line HepG2.117 for anti-HBV cccDNA screening. With the similar cloning strategy 
106 for the transgene in HepAD38 cell line and its upgraded version HepDE19 cells (Cai 
107 et al., 2012; Zhou et al., 2006), HBV production in HepG2.117 cell is also under the 
108 control of a tetracycline-responsive promoter, and the authentic HBV precore mRNA 
109 can only be transcribed from cccDNA but not the transgene, giving rise to cccDNA-
110 dependent HBeAg production (Sun and Nassal, 2006; Zhou et al., 2006). Through 
111 screening of compounds derived from Chinese herbal remedies for their activity 
112 against HBeAg production in HepG2.117 cells, three hydrolyzable tannins 
113 (Punicalagin, Punicalin and Geraniin) were identified as antiviral hits. Punicalagin, 
114 punicalin and geraniin inhibited the production of HBeAg but not HBsAg in 
115 HepG2.117 cells, along with a significant reduction of cccDNA without dramatic 
116 alteration of viral DNA replication. Further study revealed that tannins inhibited 
117 cccDNA accumulation in HepDES19 and HepG2.117 cells primarily through 
118 preventing cccDNA establishment, and partly through promoting cccDNA 
6119 degradation. These results suggested that hydrolyzable tannins represent a novel 
120 class of natural product compounds that hold promise for development of cccDNA 
121 eliminators to cure hepatitis B.
122
123 2. METHODS AND MATERIALS
124 2.1 Cell lines and cell culture
125 HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
126 (Invitrogen) supplemented with 10% FCS, 100 U/mL penicillin and 100 μg/mL 
127 streptomycin at 37℃ in 5% carbon dioxide atmosphere. HepG2.2.15 is a HepG2-
128 based stable cell line that carries two integrated tandem head-to-tail dimers of HBV 
129 genome and a G418-resistant gene (Sells et al., 1987). HepG2.2.15 cell were 
130 cultured in the same way as HepG2 cells with the addition of 500 µg/mL G418. 
131 HepG2.117, a gift from Dr. Dian-Xing Sun (University Hospital Freiburg, Germany), 
132 is an inducible HBV-replicating cell line that expresses HBV pgRNA under the 
133 control of a tetracycline responsive CMV promoter (Sun and Nassal, 2006).  
134 HepDES19 is a sibling cell line of HepDE19 cells with artificial gene mutations to 
135 block the expression of HBV envelope proteins, it produces more cccDNA than 
136 other HBV stable cell lines and thus was often used in direct cccDNA measurement 
137 by Southern blot (Cai et al., 2012; Guo et al., 2007a). HepG2.117 and HepDES19 
138 cells were cultured in the same way as HepG2.2.15 cells with additional 80 μg/mL 
139 hygromycin and 1.5 μg/mL doxycycline (Dox) (for HepG2.117 cells) or additional 1 
140 µg/mL tetracycline (Tet) (for HepDES19 cells). When needed, Dox or Tet was 
141 withdrawn to induce HBV pgRNA transcription. 
142 2.2 Natural product library screening 
143  The natural product library, which contains a large amount of compounds 
7144 (purity ≥ 98%) from Chinese traditional herbs, was obtained from Sichuan Weikeqi 
145 Biological Technology Co., Ltd. We selected 400 compounds from the natural 
146 product library to evaluate their anti-HBV activities according to the reported 
147 antiviral functions of those Chinese traditional herbs. HepG2.117 cells were plated in 
148 96-well plates at a density of 8×103 cells/well in the presence of Dox. Twenty-four 
149 hours after seeding, Dox was removed and cells were treated with natural product 
150 compounds at concentration of 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM and 100 
151 μM, and 10 µM of lamivudine (NIH AIDS Research and Reference Reagent 
152 Program, Rockville, MD, USA. purity ≥ 98%) was included as positive control, FBS 
153 and DMSO were normalized to 5% and 1% in all the mock and treatment groups, 
154 respectively. The drug-containing media were replaced every three days. The culture 
155 media were harvested at day 6 post treatment and subjected to HBeAg and HBsAg 
156 enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s 
157 instructions (Kehua, Shanghai). Compounds that reduced HBeAg more than 50% but 
158 did not reduce HBsAg were considered as hits.  
159 2.3 Cell Viability Assay
160 The effect of testing compounds on cell viability was measured by using the 
161 CellTiter-Glo reagent (Promega) according to the manufacturer’s instructions.   
162 2.4 Analysis of HBV RNA
163 Total cellular RNA was extracted with Trizol reagent (Invitrogen). HBV RNA 
164 Northern blot was performed according to previously published (Cai et al., 2012). 
165 To determine viral mRNA levels by quantitative real-time PCR, 1 μg of total 
166 cellular RNA were treated with RQ1 RNase-Free DNase (Promega) and reverse 
167 transcribed using M-MLV Reverse Transcriptase (Promega) and oligo dT (Promega) 
168 following the manufacturer’s instructions. The cDNAs of HBV total RNA, precore 
8169 mRNA and pgRNA were quantified by real-time PCR. PCRs were performed using 
170 SYBR Green PCR Master Mix and the primer pairs with the following program: 
171 initial denaturation at 95℃ for 5 min, followed by 37 cycles of amplification at 95℃ 
172 for 15 s and annealing/extension at 56℃ for 45 s.
173 The specific primers for precore mRNA were as follows: forward, 5’-
174 TCTGCGCACCAGCACCATG-3’ (nt 1800-1818); reverse, 5’-
175 TGCCTCGTCGTCTAACAA-3’ (nt 2362-2345). The forward primer for pgRNA 
176 amplification was 5’-TCGGGAAGCCTTAGAGTC-3’（nt 2016-2033）, the 
177 reverse primer was 5’-TGCCTCGTCGTCTAACAA-3’ (nt 2362-2345) (He et al., 
178 2011). The primers for total HBV RNA were 5’-CCGTCTGTCCTTCTCATCT-3’ 
179 (nt 1551-1570) and 5’-GACCAATTTATGCCTACAGCCTC-3’ (nt 1801-1779). 
180 Primers used for GAPDH mRNA amplification were as previously reported, as 5’-
181 GAAGGTGAAGGTCGGAGTC-3’ and 5’-GAAGATGGTGATGGGATTTC-3’ 
182 (Zhong et al., 2005).
183 2.5 Detection of HBV core promoter activity by dual luciferase reporter assay
184 HepG2 and Huh7 cells were transiently cotransfected with plasmid pHBVCP-
185 Luc reporter, which was constructed by inserting HBV core promoter before the 
186 firefly luciferase gene in the pGL3-basic vector , and the reporter plasmid pRL-TK 
187 as an internal control with FuGENE-HD reagent according to the manufacturer’s 
188 instructions (Roche Applied Science, Manheim, Germany) (He et al., 2011). 
189 Twenty-four hours post-transfection, cells were treated with compounds for three 
190 days with fresh media changed every day. HBV core promoter activity was 
191 determined by measuring luciferase activity using the Dual Luciferase Reporter 
192 Assay System (Promega).
193 2.6 Western blot assay
9194 Cells were treated with different concentrations of compounds for six days, 
195 washed with cold PBS, and lysed with radio immunoprecipitation assay (RIPA) lysis 
196 buffer supplemented with complete mini protease inhibitor cocktail (Roche) at 4℃ 
197 for 1 hour. Cell lysates were subjected to 15% SDS-PAGE and transferred to 
198 polyvinylidene difluoride (PVDF) membranes. After incubation with rabbit anti-
199 HBcAg (Dako) at 4℃ overnight, each blot was probed with horseradish peroxidase-
200 conjugated secondary antibody. Immunoreactive signals were detected with an 
201 enhanced chemiluminescence substrate (Thermo) using an AlphaEaseH FC Imaging 
202 System (Alpha Innotech Corporation).
203 2.7 Extraction and detection of HBV DNA
204 HepG2.117 cells were lysed with lysis buffer containing 10 mM Tris–HCl (pH 
205 7.5), 10 mM EDTA and 0.7% SDS, 150 mM NaCl. After 30 min incubation at room 
206 temperature, samples were divided into two parts, one for total DNA purification and 
207 the other for cccDNA extraction. Briefly, the total DNA containing lysate was 
208 treated with 0.4 mg/mL Proteinase K for 4 h at 58℃ followed by phenol/chloroform 
209 extraction and ethanol precipitation. For cccDNA extraction, the lysate was added 
210 0.25 volumes 2.5 M KCL and incubated at room temperature for 30 min, then 
211 clarified protein-DNA-complexes by centrifugation at 12,000×g for 10 min (Werle-
212 Lapostolle et al., 2004; Wu et al., 1990). The supernatant containing cccDNA was 
213 extracted twice with phenol/chloroform and once with chloroform. DNA was 
214 precipitated with ethanol overnight at -20℃ and dissolved in ddH2O. The cccDNA 
215 samples were heated to 85℃ to denature the non-cccDNA into single strand DNA 
216 and then treated with plasmid-safe ATP-dependent DNase (PSAD) (preferentially 
217 digest double or single stranded DNA over nicked circular dsDNA) to remove the 
218 non-cccDNA molecules. Then cccDNA was purified with PCR/DNA Purification 
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219 Kit (Beyotime, China). DNA samples were subjected to real-time PCR using SYBR 
220 GREEN Realtime PCR Master Mix (TOYOBO). To quantify total intracellular HBV 
221 DNA (core DNA and cccDNA), primers corresponding to HBV S ORF were 
222 introduced (Liu et al., 2007). CccDNA selective primers NCCC1 5’- 
223 CTCCCCGTCTGTGCCTTCT -3’ plus CCCAS2 5’- GCCCCAAAGCCACCCAAG 
224 -3’ were used for cccDNA amplification (Werle-Lapostolle et al., 2004). The 
225 quantification was normalized to the GAPDH DNA copies. Mitochondrial DNA was 
226 analyzed as an internal reference for normalization purpose for cccDNA 
227 quantification in the cccDNA decay kinetics assay. Primers for Mitochondrial DNA 
228 quantification were 5’- CCCCACAAACCCCATTACTAAACCCA -3’ plus 5’- 
229 TTTCATCATGCGGAGATGTTGGATGG -3’. 
230 The extraction and Southern blot analysis of HBV core DNA and cccDNA 
231 from HepDES19 cells were performed as previously described (Cai et al., 2013; Guo 
232 et al., 2007a). Quantitative real-time PCR detection of core DNA and cccDNA from 
233 HepDES19 cells was performed with the FastStart Essential DNA Probes Master 
234 (Roche), using a 20 µl reaction mixture. The primers and probe used for core DNA 
235 detection were forward primer: 5’- CCGTCTGTGCCTTCTCATCTG -3’, reverse 
236 primer: 5’- AGTCCAAGAGTYCTCTTATGYAAGACCTT -3’and probe: 5’-FAM- 
237 CCGTGTGCACTTCGCTTCACCTCTGC -TAMRA-3’. The PCR reaction contains 
238 0.8 µM of primers and 0.2 µM of probe and the thermal cycling conditions are as 
239 follow: 10 min at 95℃, 45 cycles of 15 s at 95℃ and 30 s at 64℃. The primers and 
240 probe used for cccDNA qPCR were forward primer 5’-
241 GTCTGTGCCTTCTCATCTGC-3’, reverse Primer: 5’-
242 AGTAACTCCACAGTAGCTCCAAATT-3’, and probe 5’-FAM-
243 TTCAAGCCTCCAAGCTGTGCCTTGGGTGGC-TAMRA-3’. The amplification 
11
244 setting included 0.9 µM primers and 0.2 µM probe, annealing, and extension at 61℃ 
245 for 50 cycles.
246 2.8 Statistical analysis
247 Statistical analysis was performed by using a two-tailed student’s t test by 
248 SPSS software. Results were presented as mean value±SD with p-value. 
249
250 3. RESULTS
251 3.1 Identification of hydrolyzable tannins as novel anti-HBV agents
252 Thus far, HepDE19 cell line remains the only reported cell system which was 
253 specially designed to express HBeAg as a cccDNA reporter and has been 
254 successfully applied in high throughput screening of small molecule compound 
255 libraries for cccDNA inhibitors (Cai et al., 2012). The principle of cccDNA-
256 dependent HBeAg expression in HepDE19 cells is built upon a transgene cloning 
257 strategy that prevents precore (the precursor of HBeAg) expression from the 
258 integrated HBV genome, but allows precore expression from cccDNA template once 
259 the separated ORF of precore on both termini of pgRNA is rejoined after reverse 
260 transcription and cccDNA formation (Cai et al., 2012; Zhou et al., 2006). In this 
261 regard, HepG2.117 cell line carries a HBV pgRNA expression cassette under the 
262 control of tetracycline inducible promoter, starting from a nucleotide right behind the 
263 start codon of precore ORF (Sun and Nassal, 2006). Theoretically, HepG2.117 cells 
264 should not make precore/HBeAg from transgene, but the pgRNA transcribed from 
265 transgene will initiate DNA replication and the precore ORF will be restored on the 
266 cccDNA, giving rise to the cccDNA-dependent HBeAg production. To test this, the 
267 kinetics of HBeAg secretion and cccDNA production upon doxycycline removal 
268 were monitored. As expected, there is a good correlation between the extracellular 
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269 levels of HBeAg and the amounts of intracellular cccDNA (Fig. S1). Therefore, the 
270 secretion of HBeAg can serve as a cccDNA surrogate marker in HepG2.117 cells, 
271 and we thus measured HBeAg to evaluate the antiviral activities of the compounds 
272 against HBV cccDNA. 
273 Among 400 compounds isolated from traditional Chinese medicinal herbs, 
274 three structurally related compounds, specifically punicalagin, punicalin and geraniin, 
275 emerged as confirmed hits from the screening. Punicalagin, punicalin and geraniin 
276 are hydrolyzable tannins as they possess structures that generally consist of gallic or 
277 ellagic acid esters conjugated to a sugar moiety (Khanbabaee and van Ree, 2001) 
278 (Fig. 1). All the three tannins exhibited dose-dependent reduction of supernatant 
279 HBeAg level in HepG2.117 cells but had no effect on the secretion of HBsAg at 
280 non-cytotoxic doses (Fig. 2A, 2B and 2C). Next, we chose punicalagin as a 
281 representative compound to test its effect on core protein expression by Western Blot. 
282 As shown in Fig. 2D, punicalagin did not affect the expression of core protein, which 
283 was predominantly expressed from the HBV transgene in HepG2.117 cells. These 
284 results demonstrated that hydrolyzable tannins displayed a specific inhibition of 
285 HBeAg production in HepG2.117 cells, inferring a possible antiviral effect of 
286 tannins on cccDNA synthesis, stability, or transcription.
287 3.2 Punicalagin treatment reduced HBV precore mRNA level in HepG2.117 
288 cells
289 Since the authentic precore mRNA is only transcribed from cccDNA template 
290 in HepG2.117 cells, but other HBV RNAs, such as pgRNA, should be predominantly 
291 synthesized by using transgene as template, precore mRNA, pgRNA and total HBV 
292 RNA were examined to evaluate the antiviral specificity of punicalagin on HBV 
293 RNA production. Because precore mRNA is only 35 nt longer than pgRNA at the 5’ 
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294 terminus, in order to distinguish precore mRNA from pgRNA in PCR assay, we used 
295 a specific forward primer (nt 1800-1818) in the 5’-end 35 nt region of precore RNA, 
296 which is absent in pgRNA, and the reverse primer (nt 2362-2345) is present in both 
297 precore mRNA and pgRNA, to amplify precore mRNA (He et al., 2011). Another 
298 pair of primers that amplifies a fragment of core ORF was used to detect both 
299 pgRNA and precore mRNA. Since all HBV mRNAs contain the same sequence of X 
300 mRNA, a pair of primers flanking the X ORF region was utilized to amplify HBV 
301 total RNA (Fig. 3A). As shown in Fig. 3B, the treatment of punicalagin significantly 
302 reduced the levels of precore mRNA in HepG2.117 cells, but had no impact on the 
303 levels of pgRNA and total mRNAs, suggesting that punicalagin treatment may 
304 reduce the accumulation of cccDNA or block cccDNA transcription. It is worth to 
305 note that, although either the reduction of cccDNA copy number or inhibition of 
306 cccDNA transcription will result in the loss of cccDNA-derived HBV pgRNA and 
307 total RNA levels, such contribution from cccDNA has been shown to be minor 
308 compared to that from transgene in HBV stable cell lines (Cai et al., 2012; Chou et 
309 al., 2005; Guo et al., 2007b), thus the levels of pgRNA and total HBV RNA 
310 remained unchanged under 3TC or punicalagin treatment (Fig. 3B).    
311 Next, we tested punicalagin in HepG2.2.15 cells, in which all the viral RNAs 
312 are constitutively and predominately transcribed from the integrated HBV genome. 
313 As shown in Fig. 3C, 3TC or punicalagin treatment did not down-regulate precore 
314 mRNA, pgRNA or HBV total mRNAs at all in HepG2.2.15 cells, suggesting that 
315 punicalagin specifically reduces the level of precore mRNA with cccDNA being the 
316 exclusive transcription template.
317 3.3 Punicalagin has no impact on the precore/core promoter activity 
318 As shown above, precore mRNA was down-regulated by punicalagin in 
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319 HepG2.117 cells but not in HepG2.2.15 cells. Considering precore mRNA can be 
320 transcribed under the control of viral precore/core promoter from cccDNA template 
321 in HepG2.117 cells, or from both integrated viral DNA (major) and cccDNA (minor) 
322 templates in HepG2.2.15 cells, it is possible that punicalagin may inhibit HBV basal 
323 core promoter in an episomal DNA template. To test this possibility, we examined 
324 the effect of punicalagin on precore/core promoter activity by using the reporter 
325 plasmid pHBVCP-Luc. The results showed that punicalagin did not suppress the 
326 transcriptional activity of HBV core promoter in HepG2 cells (Fig. 3D) or in Huh7 
327 cells (data not shown) at non-cytotoxic doses.
328 3.4 Punicalagin inhibits the accumulation of cccDNA in HepG2.117 cells 
329  The above data demonstrated that punicalagin specifically down-regulated 
330 the production of cccDNA-dependent precore mRNA and HBeAg without affecting 
331 precore/core promoter activity, we thus speculated that the observed antiviral effect 
332 of punicalagin might be a consequence of the decreased level of HBV cccDNA upon 
333 treatment. To evaluate the effect of punicalagin on cccDNA, HepG2.117 cells were 
334 treated with or without punicalagin from the third day after the removal of 
335 doxycycline and lasted for 3 days. Then total DNA and cccDNA were extracted and 
336 subjected to real-time PCR quantification. As shown in Fig. 4A, punicalagin 
337 markedly reduced the levels of cccDNA in a dose-dependent manner, but only 
338 slightly reduced the amount of total HBV DNA at higher concentrations. DNA from 
339 HepG2.117 cells treated with doxycycline (Dox) and core DNA in the supernatant of 
340 HepG2.117 cells without doxycycline were included as negative controls for 
341 cccDNA qPCR. It has been reported that HBV DNA and HBeAg significantly 
342 accumulated from the third day after Dox induction in HepG2.117 cells (Sun and 
343 Nassal, 2006). Thus, we reasoned that the observed weak effect of 3TC on levels of 
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344 cccDNA (Fig. 4A) and precore RNA (Fig. 3B) in HepG2.117 cells after 3-day Dox 
345 induction might be due to an established cccDNA pool before treatment or a fast 
346 dynamics of rcDNA to cccDNA conversion. To further confirm the inhibitory effect 
347 of punicalagin on the accumulation of HBV cccDNA, HepG2.2.15 cell line was 
348 treated with punicalagin and a similar result was observed in this cell line, though it 
349 had an obvious effect until the treatment was extended to 6 days (Fig.4 B). Taken 
350 together, these results demonstrated that punicalagin has a direct down-regulative 
351 effect on the accumulation of cccDNA.  
352 3.5 Hydrolyzable tannins directly inhibit cccDNA production in HepDES19 cells 
353 To further confirm the inhibitory effects of tannins on cccDNA accumulation, 
354 HepDES19 cells were treated with punicalagin, punicalin and geraniin immediately 
355 after withdrawal of tetracycline. HepDES19 supports the replication of an envelope-
356 deficient HBV genome in a tetracycline-inducible manner. After induction, the cells 
357 exhibit a higher ratio of cccDNA to rcDNA than cells that contain wild-type HBV 
358 genome, likely due to the loss of negative regulations of viral envelope proteins on 
359 cccDNA amplification (Guo et al., 2007a; Lentz and Loeb, 2011). As shown in Fig. 
360 5, except that punicalagin exhibited cytotoxicity at 30 μΜ after 2-week treatment, all 
361 three tannins resulted in a dose-dependent reduction of cccDNA in HepEDS19 cells 
362 without dramatic alterations of the steady state levels of viral RNA, core DNA, and 
363 deproteinized rcDNA (DP-rcDNA), which is consistent with the observations in 
364 HepG2.117 and HepG2.2.15 cells. Furthermore, quantitative PCR analyses 
365 demonstrated the similar results with DNA Southern blot. All these results clearly 
366 suggest that hydrolyzable tannins inhibit HBV cccDNA accumulation at a post DNA 
367 replication step(s).
368 3.6 Tannins modestly promote the decay of cccDNA
16
369 In stably transfected HBV cell cultures, the maintenance of cccDNA pool is 
370 relying on the intracellular rcDNA to cccDNA amplification pathway and the 
371 longevity of cccDNA (Guo and Guo, 2015). To elucidate the antiviral mechanism by 
372 which HBV cccDNA was affected by tannins, we made use of the inducible 
373 HepDES19 cells to assess the stability of cccDNA under compound treatment. As 
374 shown in Fig. 6 A and B, HBV core DNA, DP-rcDNA and cccDNA accumulated at 
375 day 12 after the removal of tetracycline, then the de novo synthesis of cccDNA was 
376 inhibited by treating the cells with tetracycline and 3TC to shut down the transgene-
377 based pgRNA transcription and viral DNA replication, respectively. Four days later, 
378 the decay kinetics of existing core DNA, DP-rcDNA, and cccDNA were determined 
379 with or without tannins treatment in the continuous presence of tetracycline and 3TC. 
380 The results revealed the following observations: 1) all three types of HBV DNA 
381 species degraded gradually over time, cccDNA was more stable than core DNA and 
382 DP-rcDNA (Fig.6 B,C,D); 2) tannins did not alter the decay kinetics of cytoplasmic 
383 core DNA (Fig. 6B, upper panel); 3) among these three tannins, punicalagin and 
384 punicalin modestly but clearly promoted the degradation of DP-rcDNA and cccDNA, 
385 but geraniin had little effect on the stability of either DNA molecules (Fig. 6 B,C,D); 
386 In order to quantitatively measure the tannin-mediated cccDNA decay and to rule out 
387 the possible cell line specific effect, HepG2.117 cells were tested with three tannins 
388 for the cccDNA decay kinetics, a similar result was observed in this cell line (Fig. 
389 S2). However, comparing the antiviral effect of tannins on the accumulation of 
390 cccDNA to its stability (Fig. 5 vs. Fig. 6; Fig. 4 vs. Fig. S2), we speculate that the 
391 acceleration of cccDNA decay plays less important role than preventing cccDNA 
392 formation in the observed inhibition of cccDNA accumulation by tannins, although a 
393 possible stronger effect of tannins on cccDNA stability in the early cccDNA 
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394 establishing phase could not be completely ruled out. Nevertheless, our data suggest 
395 that hydrolyzable tannins inhibit HBV cccDNA through a dual mode of action, by 
396 blocking cccDNA formation and promoting cccDNA degradation, though the latter 
397 effect is rather minor.
398
399 4. DISCUSSION
400 Continuous development of new agents to treat HBV infections is urgently 
401 needed because of the limitation and side effects of current available drugs, and 
402 antiviral substances that are able to eradicate cccDNA from HBV infected 
403 hepatocytes are highly warranted (Guo and Guo, 2015; Zoulim and Durantel, 2015). 
404 Traditional Chinese medicine (TCM) is used extensively for the treatment of CHB in 
405 China. Thousands of different herbs have been used in numerous TCM formulations 
406 (mixture of different herbs) for the treatment of CHB. Many TCMs and related 
407 active compounds have been reported to have promising and potent anti-HBV 
408 activities. These compounds including Phyllanthus, Salvia miltiorrhiza, Rheum 
409 palmatum L., Radix Astragali, oxymatrine, artemisinin and artesunate, and wogonin 
410 (Cui et al., 2010). A meta-analysis of randomized, controlled, clinical trials (RCTs) 
411 of TCM for treatment of CHB with either TCM alone or in combination with 
412 interferon or lamivudine revealed that: (i) TCM had a greater beneficial effect than 
413 IFN and slightly better effect than lamivudine on normalization of serum ALT; (ii) 
414 TCM had a similar beneficial effect when compared with IFN or lamivudine for 
415 CHB on antiviral activity as evidenced by the loss of serum HBeAg and HBV DNA; 
416 (iii) TCM enhanced IFN and lamivudine antiviral activities and improvements of 
417 liver function (Zhang et al., 2009). Thus, TCM can serve as a resource for 
418 identification of direct anti-HBV drug.
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419 To identify new drug candidates against HBV cccDNA, we screened 400 
420 compounds isolated from traditional Chinese medicinal herbs via a cell-based assay 
421 using HBeAg as cccDNA reporter, and three hydrolyzable tannins (punicalagin, 
422 punicalin and geraniin) were found to possess potent inhibition activity on HBeAg 
423 secretion and cccDNA establishment. Interestingly, hydrolyzable tannins have been 
424 reported to exhibit antiviral activities against viral adsorption to the host cell 
425 membrane (for HSV and HIV), as well as HIV reverse transcriptase (Buzzini et al., 
426 2008; Serrano et al., 2009). Haidari et al. found that punicalagin blocked the 
427 replication of the influenza virus RNA, inhibited agglutination of chicken red blood 
428 cells by the virus and had virucidal effects. In addition, punicalagin synergized the 
429 anti-influenza activity of oseltamivir (Haidari et al., 2009). Punicalagin and geraniin 
430 have been reported to inhibit EV71 infection both in vitro and in vivo (Yang et al., 
431 2012a; Yang et al., 2012b). These observations, together with our findings, suggest 
432 that tannins possess a broad antiviral spectrum.
433 In our attempt to characterize the antiviral target(s) of tannins in HBV life 
434 cycle, we found that tannins down regulated the level of cccDNA in HBV stable cell 
435 lines without inhibiting viral RNA transcription and DNA replication, indicating that 
436 tannins directly target cccDNA metabolism. Further analyses demonstrated a 
437 potential dual mode of action of tannins against cccDNA homeostasis. First, tannins, 
438 especially punicalagin and punicalin, were able to modestly promote the degradation 
439 of preexisting cccDNA and DP-rcDNA, the latter has been suggested to be a 
440 precursor for cccDNA (Gao and Hu, 2007; Guo et al., 2007a; Guo et al., 2010). 
441 However, the degree of cccDNA reduction through degradation could not account 
442 for the total reduction of cccDNA under tannin treatment (comparing Fig. 6 to Fig. 
443 5), not to mention that geraniin had little effect on the stability of both DNA 
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444 molecules (Fig. 6). In addition, the degradation of DP-rcDNA during active virus 
445 replication, if any, was negligible (Fig. 5A). Thus, we speculated that tannins, 
446 especially geraniin, possess a major antiviral activity against cccDNA formation. 
447 Nevertheless, since the assays of tannin’s antiviral effect on cccDNA accumulation 
448 and stability were performed under different experimental conditions, such as the 
449 timing and duration of treatment, cell density and vitality, and the presence of other 
450 drugs, a possible stronger inhibitory effect of tannins on cccDNA stability during the 
451 early phase of cccDNA establishment cannot be completely ruled out.
452 It is not unprecedented that tannins possess more than one antiviral activity 
453 against HBV. Hydrolyzable tannins are known to be hydrolyzed into smaller 
454 polyphenols, such as gallic or ellagic acids, it is therefore conceivable that the 
455 inhibition of cccDNA formation and stability by tannin is attributed to different 
456 hydrolysis products and/or other metabolites. Gallic or ellagic acids have been 
457 shown to inhibit multiple steps in HBV life cycle, including virus entry (Huang et 
458 al., 2014), DNA replication (He et al., 2011; Zhong et al., 2015), and HBeAg 
459 secretion (Shin et al., 2005). However, the direct effect of hydrolyzable tannins on 
460 cccDNA metabolism has not been studied. In the present study, we, for the first time, 
461 identified and characterized the bivalent antiviral activities of tannins against 
462 cccDNA. Comparing these three tannins in the current study, punicalagin and 
463 punicalin are more structurally closely related and both tannins could be hydrolyzed 
464 into an identical ellagic acid-containing fragment, while the hydrolysis of geraniin 
465 will produce gallic acid instead, which may explain the observed similar antiviral 
466 activity between punicalagin and punicalin and the less inhibitory effect of geraniin 
467 on cccDNA stability. What’s more, hydrolysis of punicalagin will generate an 
468 additional C-C bond connected dimeric gallic acids. Therefore, it is of interest to test 
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469 each individual tannin metabolites to distinguish their effects on cccDNA in the 
470 future study.      
471 Despite of the key role of cccDNA in HBV infection, thus far little is known 
472 about cccDNA formation and maintenance. Comparing the structure of cccDNA to 
473 that of rcDNA, the conversion of rcDNA to cccDNA requires: (i) removal of viral 
474 polymerase covalently attached to the 5’ end of the negative DNA strand; (ii) 
475 removal of the 5’–capped short RNA primer on plus-strand DNA; (iii) the 
476 completion of viral plus-strand DNA; (iv) the removal of one copy of the short 
477 terminal redundancy from the minus-strand DNA;（v）the ligation of two viral 
478 strands (Cai et al., 2012; Guo et al., 2007a; Guo and Guo, 2015; Levrero et al., 
479 2009). The only known viral proteins to regulate cccDNA formation from mature 
480 rcDNA are the viral envelope proteins which were shown to suppress cccDNA 
481 amplification by a negative-feedback mechanism (Lentz and Loeb, 2011; Summers 
482 et al., 1990). It is widely accepted that host DNA repair machinery is involved in 
483 cccDNA formation, this notion is supported by evidence showing that the host non-
484 homologues end joining (NHEJ) pathway is required for conversion of duck 
485 hepatitis B virus (DHBV) double stranded linear DNA into cccDNA (Guo et al., 
486 2012). However, host DNA repair factors that participate in authentic cccDNA 
487 formation from rcDNA have not been identified. As discussed above, cccDNA 
488 formation requires the removal of viral polymerase covalently attached to rcDNA, 
489 this deproteinization reaction generates a DP-rcDNA as functional precursor for 
490 cccDNA and may serve as an antiviral target. Recently, two structurally related 
491 disubstituted sulfonamides, CCC-0975 and CCC-0346, have been identified as 
492 cccDDNA formation inhibitors through high throughput compound screening, 
493 which interfere primarily with rcDNA conversion into cccDNA by reducing the 
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494 cccDNA putative precursor DP-rcDNA. In the present study, punicalagin, punicalin 
495 and geraniin inhibited cccDNA formation not by suppressing the production of DP-
496 rcDNA (Fig. 5A), which imply that the hydrolyzable tannins impair cccDNA 
497 biosynthesis through a novel mechanism. Regarding the stability of cccDNA, it is 
498 known that cccDNA exists in nucleus as a nucleosome-decorated minichromosome, 
499 however, critical questions, such as, whether or not nuclear DP-rcDNA is a 
500 minichromosome, how does cccDNA minichromosome maintain its stability, 
501 whether cccDNA unpacks its chromatin architecture during mitosis, and whether 
502 cccDNA survives cell division, remain unanswered. Interestingly, we found that 
503 punicalagin and punicalin exhibited activity to promote cccDNA and DP-rcDNA 
504 degradation, albeit at a low potency, indicating that the chemical approach to 
505 eliminate nuclear non-host episomal viral DNA is feasible. More importantly, 
506 eradication of cccDNA from infected hepatocytes is an undisputed holy grail for a 
507 definite cure of hepatitis B. To our best knowledge, punicalagin and punicalin are 
508 the only chemical compounds that have been reported to reduce the stability of 
509 preexisting cccDNA in cell cultures, albeit the potency is rather modest. On the 
510 other hand, further study of the mechanism of action of hydrolyzable tannins, 
511 including identification of their exact antiviral targets, will reciprocally lead to a 
512 better understanding of the mechanisms of cccDNA formation and maintenance. 
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526 Figure legends
527  Fig. 1 Chemical structures of punicalagin, punicalin and geraniin.  
528 Fig. 2 Identification of punicalagin, punicalin and geraniin as novel anti-HBV 
529 agents. After the induction of HBV replication, HepG2.117 cells were treated with 
530 various indicated concentrations of compounds for six days. (A) Cell viability was 
531 measured to assess the compound cytotoxicity. HBeAg (B) and HBsAg (C) in the 
532 culture supernatants were determined by ELISA. Error bars indicate standard 
533 deviation of three independent experiments. (D) Intracellular HBV core protein was 
534 analyzed by Western blot. β-Actin served as loading control. 
535 Fig. 3 Punicalagin downregulates levels of precore mRNA in HepG2.117 cells, 
536 but has no effect on core promoter activity. （A）Schematic illustration of HBV 
537 RNAs and the PCR primer positions. The primers for precore mRNA detection are 
538 primer “+” (nt 1800-1818) and primer “-” (nt 2362-2345). Primer “+” (nt 2016-2033) 
539 and primer “-” (nt 2362-2345) were used for pgRNA and precore mRNA 
540 amplification. A pair of primers flanking the X ORF region, primer “+” (nt 1551-
541 1570) and primer “-” (nt 1801-1779), were used to amplify HBV total RNA. (B) 
542 After induction of HBV replication for three days in the absence of Dox, HepG2.117 
543 cells were treated with various concentrations of punicalagin and lamividine (3TC, 1 
544 μM) for an additional three days and harvested for total RNA extraction. Viral RNAs 
545 were detected by real-time PCR. GAPDH was analyzed as an internal reference for 
546 normalization purpose. C, untreated control. (C) HepG2.2.15 cells were treated with 
547 drugs for 3 days and harvested for total RNA extraction. Viral RNAs were detected 
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548 by real-time PCR. (D) Twenty four hours after cotransfection with pHBVCP-Luc 
549 and pRL-TK, HepG2 cells were treated with different concentrations of punicalagin 
550 for 3 days and lysed for dual luciferase reporter analysis. 
551 Fig. 4 Punicalagin treatment reduces cccDNA level in both HepG2.117 and 
552 HepG2.2.15 cells. Cells were treated with punicalagin at different concentrations for 
553 the indicated time. Cells were collected and DNAs were extracted and analyzed by 
554 specific real-time qPCR. GAPDH was used for normalization. DNA level in the 
555 untreated control was arbitrarily designated as 1. Error bars indicate standard 
556 deviation of three independent experiments. (A) After induction of HBV replication 
557 for three days, HepG2.117 cells were treated with various concentrations of 
558 punicalagin and lamividine (3TC, 1 μM) in the absence of Dox for an additional 
559 three days. Intracellular total HBV DNA and cccDNA were detected. C, untreated 
560 control; Dox, DNA from the cells treated with Dox, used as negative control for 
561 cccDNA qPCR to assess the contamination of the integrated HBV DNA; S-RC, 
562 supernatant DNA (2.0×105 copies/ml) from HepG2.117 cells cultured in the absence 
563 of Dox was treated by PSAD and used as negative control for cccDNA qPCR to 
564 assess the contamination of RC DNA. (B) HepG2.2.15 cells were treated with drugs 
565 for six days and the effect of punicalagin on intracellular HBV total DNA and 
566 cccDNA was determined. Data were expressed as mean ±S.D. (n=3).
567 Fig. 5 Hydrolyzable tannins directly inhibit cccDNA production in HepDES19 
568 cells. HepDES19 cells were untreated (UNT) or treated with punicalagin, punicalin 
569 or geraniin at the indicated concentrations upon withdrawal of tetracycline. The 
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570 treatment was repeated every two days and cells were harvested at day 14 post 
571 treatment, viral RNA (top panel), core DNA (middle panel), and Hirt DNAs (DP-
572 rcDNA and cccDNA) (bottom two panels, the blot with longer exposure was used to 
573 highlight cccDNA bands) were extracted and analyzed by Northern blotting and 
574 Southern blotting, respectively (A). HBV cytoplasmic core DNA (B) and cccDNA 
575 (C) were also quantified by qPCR. The quantitative data was normalized to untreated 
576 control and expressed as mean ± SD (n=3).
577 Fig. 6 The effects of tannins on the decay kinetics of HBV DP-rcDNA and 
578 cccDNA in HepDES19 cells. (A) Schematic illustration of experimental procedures: 
579 HepDES19 cells were cultured in 6-well plate in the presence of tetracycline until 
580 the cells reached confluent state, then tetracycline was removed from the culture 
581 medium to induce HBV replication and cccDNA formation. After 12 days, 
582 tetracycline and 3TC (10 μM) were added back to the culture medium to shut off 
583 viral pgRNA transcription from the integrated HBV genome and prevent viral DNA 
584 replication. Four days later, one set of cells were cultured with medium containing 
585 tetracycline and 3TC and another three sets of cells were treated with the tannins in 
586 the presence of tetracycline and 3TC for the indicated period of time. (B) Cells were 
587 harvested at the indicated time points, HBV core DNA and Hirt DNA were analyzed 
588 by Southern blot. The relative intensities of viral DP-rcDNA and cccDNA signals in 
589 each sample were expressed as percentages of the signals from the sample at day 16 
590 (lane 2 in panel B) and were plotted in graphs C and D, respectively. 
591 Fig. S1 Evaluation of cccDNA-dependent HBeAg production on HepG2.117 cells. 
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592 HepG2.117 cells were plated in 24-well plates in Dox-containing medium and 
593 cultured until confluent, then Dox was removed from the medium (day 0). Cells were 
594 cultured for another 12 days. Cells and medium were harvested every other day from 
595 day 0 to 12. HBeAg levels in the media were determined by ELISA. CccDNA was 
596 extracted and quantified by qPCR. At each indicated time point, the HBeAg level 
597 (right Y-axis) was superimposed to the cccDNA copy number (left Y-axis) on the 
598 graphic plot.
599 Fig. S2. The effects of tannins on the decay kinetics of cccDNA in HepG2.117 
600 cells. HepG2.117 cells were cultured in 24-well plate in the presence of Dox until the 
601 cells reached confluent state, then Dox was removed from the culture medium to 
602 induce HBV replication and cccDNA formation. After 12 days, Dox and 3TC (10 
603 μM) were added back to the culture medium to shut off viral pgRNA transcription 
604 from the integrated HBV genome and prevent viral DNA replication. Two days later, 
605 one set of cells were cultured with medium containing Dox and 3TC and another 
606 three sets of cells were treated with the indicated tannin (10 μM) in the presence of 
607 Dox and 3TC. (A) Cells were harvested at the indicated time points, cccDNA was 
608 quantified by qPCR. Mitochondrial DNA was analyzed by qPCR as an internal 
609 reference for normalization purpose. The quantitative data were normalized to D14 
610 group and expressed as mean ± SD (n=3). (B) Statistical difference analysis of 
611 cccDNA levels at day 20 in Fig.S2A. The quantitative data were normalized to D14 
612 group (control) and expressed as mean ± SD (n=3). Data were analyzed by using a 
613 two-tailed student’s t test. A p-value less than 0.05 was considered statistically 
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614 significant. *P < 0.05, **P < 0.01.
615
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Highlights:
 Eradication of HBV cccDNA is required for a definite cure of hepatitis B.
 Three hydrolyzable tannins were identified as cccDNA inhibitors from screening 400
natural compounds.
 Hydrolyzable  tannins  inhibit  cccDNA  establishment  through  inhibiting  cccDNA
formation and promoting cccDNA degradation. 
